18:36 , Nov 30, 2017 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: November 2017

New Therapeutic Targets and Biomarkers: November 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during November 2017. Therapeutic targets are defined as any protein, gene or other molecule...
22:59 , Nov 14, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Frontotemporal dementia Cell culture and mouse studies suggest inhibiting proteolytic processing of CDK5R1 into its truncated form could help treat frontotemporal dementia (FTD). In FTD patient-derived cerebral organoids, knock-in of a non-cleavable variant of CDK5R1...
01:10 , Dec 7, 2016 |  BC Extra  |  Clinical News

GNS identifies disease drivers from CoMMpass data

GNS Healthcare Inc. (Cambridge, Mass.) said it has identified four genes as "top drivers" of high-risk multiple myeloma. Using its machine learning technology, the company is collaborating with the Multiple Myeloma Research Foundation (MMRF) to...
07:00 , Sep 15, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Activator protein-1 (AP-1; JUN); CDK5 regulatory subunit associated protein 1 (CDK5RAP1)

Endocrine/metabolic disease INDICATION: Diabetes Cell culture and mouse studies suggest AP-1 inhibitors could help treat Type II diabetes involving CDK5RAP1 mutations. In human pancreatic β cells generated from induced pluripotent stem (iPS) cells harboring mutant CDK5RAP1, an...
07:00 , Aug 18, 2016 |  BC Innovations  |  Translation in Brief

The CDK5 checkpoint

Despite the clinical success of checkpoint inhibitors, immuno-oncologists still have an incomplete understanding of how the receptors and their ligands prevent antitumor immunity. In a new study, Case Western Reserve University researchers found mechanistic data...
07:00 , Aug 4, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Cyclin dependent kinase 5 (CDK5)

Cancer INDICATION: Brain cancer; cancer Patient sample and mouse studies suggest inhibiting CDK5 could help treat medulloblastoma and other cancers. In six medulloblastoma patients, high tumor levels of CDK5 were associated with low T cell infiltration into...
08:00 , Dec 14, 2015 |  BioCentury  |  Product Development

Following CoMMpass

Amidst a flood of promising data for hot targets, indications and technologies at this year's American Society of Hematology meeting, one collection of presentations stands out not only for the wide-reaching implications of their data,...
08:00 , Nov 16, 2015 |  BC Week In Review  |  Clinical News

CYC065: Phase I started

Cyclacel began an open-label, dose-escalation, U.S. Phase I trial to evaluate oral CYC065 every 3 weeks in about 35 patients. Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC), Berkeley Heights, N.J.   Product: CYC065   Business: Cancer   Molecular target: ...
07:00 , Sep 19, 2013 |  BC Innovations  |  Tools & Techniques

Brain in a dish

Austrian researchers grabbed headlines last month when they coaxed cultured human induced pluripotent stem cells into forming brain tissue,1 but in actuality the approach does not offer applications beyond studying very early brain development. Engineering stem...
07:00 , Jul 18, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) Cyclin dependent kinase 5 (CDK5); glycogen synthase kinase 3b (GSK3B)...